Abstract:In systems biology and pharmacology, large-scale kinetic models are used to study the dynamic response of a system to a specific input or stimulus. While in many applications, a deeper understanding of the input-response behaviour is highly desirable, it is often hindered by the large number of molecular species and the complexity of the interactions. An approach that identifies key molecular species for a given input-response relationship and characterises dynamic properties of states is therefore highly desirable. We introduce the concept of index analysis; it is based on different time- and state-dependent quantities (indices) to identify important dynamic characteristics of molecular species. All indices are defined for a specific pair of input and response variables as well as for a specific magnitude of the input. In application to a large-scale kinetic model of the EGFR signalling cascade, we identified different phases of signal transduction, the peculiar role of Phosphatase3 during signal activation and Ras recycling during signal onset. In addition, we discuss the challenges and pitfalls of interpreting the relevance of molecular species based on knock-out simulation studies, and provide an alternative view on conflicting results on the importance of parallel EGFR downstream pathways. Beyond the applications in model interpretation, index analysis is envisioned to be a valuable tool in model reduction. In systems biology, the response of signalling networks to various molecular stimuli is studied through large and complex kinetic models. Prominent examples include the epidermal growth factor receptor signalling cascade and its response to growth factors or therapeutic interventions by small molecules and therapeutic protein drugs. The design of targeted interventions requires a detailed understanding of the signalling cascade, the identification of key molecular constituents and their functional role in propagating the signal. A quantitative analysis of such systems, however, is challenging due the size of the model and the complexity of molecular interactions. We present an approach based on time- and state dependent quantities that are called indices and quantify different characteristic dynamic features of the molecular constituents. This allows for a more in-depth understanding of how the signal propagates through the network and elicits its response. Our findings for the epidermal growth factor receptor signalling cascade provide new insights on the dynamic interplay of key molecular players.

Use of mathematics to guide target selection in systems pharmacology; application to receptor tyrosine kinase (RTK) pathways

Cross-membrane signal transduction of receptor tyrosine kinases (RTKs): from systems biology to systems pharmacology

Predicting Drug Combination Index and Simulating the Network-Regulation Dynamics by Mathematical Modeling of Drug-Targeted EGFR-ERK Signaling Pathway

Effective Reaction-Based De Novo Strategy for Kinase Targets: A Case Study on MERTK Inhibitors

Application of Mathematical Modeling and Computational Tools in the Modern Drug Design and Development Process

Exploring the Impact of Pharmacological Target-Mediated Low Plasma Exposure in Lead Compound Selection in Drug Discovery – A Modeling Approach

Model-based Target Pharmacology Assessment (mTPA): An Approach Using PBPK/PD Modeling and Machine Learning to Design Medicinal Chemistry and DMPK Strategies in Early Drug Discovery

Know your molecule: pharmacological characterization of drug candidates to enhance efficacy and reduce late-stage attrition

Graph theory enables drug repurposing. How a mathematical model can drive the discovery of hidden Mechanisms of Action

Quantifying Cancer Drug Targetability across Biochemical Pathways

Prediction of Drug Targets for Specific Diseases Leveraging Gene Perturbation Data: A Machine Learning Approach

A Pathway Profile-Based Method for Drug Repositioning

Pharmacometric and statistical considerations for dose optimization

Index analysis: An approach to understand signal transduction with application to the EGFR signalling pathway

Mediating kinase activity in Ras-mutant cancer: potential for an individualised approach?

Targeting the Non-Catalytic Functions: a New Paradigm for Kinase Drug Discovery?

Targeting cancer with small molecule kinase inhibitors

Prioritising genetic findings for drug target identification and validation

Minireview: Targeting GPCR Activated ERK Pathways for Drug Discovery

Selection and Validation of Drug Targets